0213 GMT - Sonic Healthcare could have to agree to asset divestments before antitrust regulators approve its acquisition of German lab group LADR, Jarden analysts say. They point out in a note that the Australian pathology provider already has a 20%-25% market share in Germany, which would surpass 30% with the deal and yet further with another deal slated for 2027. The analysts see risk of antitrust issues and warn that any forced asset sales could change the economics of the acquisition. Jarden lifts its target price 3.5% to A$29.04 and keeps a neutral rating on the stock, which is down 0.2% at A$28.55. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 09, 2024 21:13 ET (02:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.